LIGELIZUMAB
UNII L8LE0L691T

Substance Identification & Data

This profile provides standardized clinical and technical data for Ligelizumab, uniquely identified by the FDA Unique Ingredient Identifier (UNII) L8LE0L691T.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 1322627-61-1 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

L8LE0L691T

CAS Registry Number

1322627-61-1

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

LIGELIZUMAB

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C175809

National Cancer Institute reference terminology for clinical and research data.

INN ID

9653

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

CD-23

Identifier assigned by the United States Adopted Names Council.

Substance Type

protein

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Ligelizumab. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

LIGELIZUMAB

Common Names & Synonyms

IMMUNOGLOBULIN G1, ANTI-(HUMAN IMMUNOGLOBULIN E) (HUMAN-MUS MUSCULUS MONOCLONAL CLONE CL-2C .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL CLONE CL-2C .KAPPA.-CHAIN, DIMER

LIGELIZUMAB [INN]

LIGELIZUMAB [JAN]

LIGELIZUMAB [USAN]

LIGELIZUMAB [WHO-DD]